CRYOARNOLD: Cryoneurolysis of Arnold's Nerve and Follow-up by Tractography: Feasibility Study

Sponsor
University Hospital, Grenoble (Other)
Overall Status
Terminated
CT.gov ID
NCT03735914
Collaborator
(none)
1
1
1
12
0.1

Study Details

Study Description

Brief Summary

According to the World Health Organization (WHO), headaches are one of the most common nervous system disorders. The therapeutic strategy is well established for certain subcategories of headache. On the other hand, when headaches become refractory, some nerves may become the target of targeted therapies. This is the case of the Arnold nerve, also called the great occipital nerve, which is involved in certain pathologies, both physiopathologically and therapeutically. The Arnold nerve infiltration has a relatively short duration of effectiveness (about 1 month on average), some teams have reported the interest of achieving a destruction of the Arnold nerve by radio frequency, with extended durations of efficiencies to several months. The use of cryoneurolysis has been known for a long time and its effectiveness in the management of cranio-facial pain is already reported. It is thus possible to obtain, at the end of the cryoanalgesia needle, very low temperatures around -40 ° C, which leads to the formation of an ice cube and, where appropriate, the freezing of the structures (nerves among others) to the needle contacts. This induces the formation of microcrystals leading to irreversible lesions of vasa-nervorums resulting in an endoneural edema. In the long run, it appears a Wallerian degeneration without destruction of this endoneurum. This is associated with the lack of destruction of the structure of the Schwann cell. Nerve regeneration is possible.

The diffusion MRI study allows tractographic reconstruction of the nerves. This is the only imaging technique that focuses on the fibrillar structure of the nerves, thus enabling the detection of nerves throughout its path. It is a morphological imaging technique nevertheless it also allows a quantitative analysis of the nerve through certain parameters.

The Investigators hypothesize that the cryoneurolysis of the Arnold nerve will result in the disappearance of visualization of the nerve by MRI tractography. The effect of cryoneurolysis on Arnold nerves, as on other peripheral nerves through diffusion MRI has never been described. The follow-up of MRI patients who had undergone cryoneurolysis would make it possible to study the behavior of these nerves after cryoneurolysis, and to correlate the aspect in tractography with the clinical data. Painful recurrence can then be correlated with visualization of the nerves by MRI.

Condition or Disease Intervention/Treatment Phase
  • Other: MRI
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
1 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Cryoneurolysis of Arnold's Nerve and Follow-up by Tractography: Feasibility Study
Actual Study Start Date :
Mar 25, 2019
Actual Primary Completion Date :
Mar 24, 2020
Actual Study Completion Date :
Mar 24, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: neuralgic patients

MRI experimentation

Other: MRI
Neuralgic patients for which a cryoneurolysis has been indicated, will passed an MRI befor and after the cryoneurolysis to check the presence of the nerve.

Outcome Measures

Primary Outcome Measures

  1. Morphological effect of Arnold's nerve cryoneurolysis [one month]

    Visualization of Arnold's nerve after tracer cryoneurolysis by MRI

Secondary Outcome Measures

  1. analgesic efficacy of the cryoneurolysis of Arnold's nerve :Measure of pain with a numeric pain scale between 0 (no pain) to 10 (intolerable) [day 7, one month, 3 months, 6 months, 12 months]

    Measure of pain with a numeric pain scale between 0 (no pain) to 10 (intolerable)

  2. Functional Impact of Pain-Related Disability After Cryoneurolysis by the Pain Disability Index Scale [day 7, one month, 3 months, 6 months, 12 months]

    Score in Pain Disability Index Scale. This scale measure the interference of pain on daily activities. There are 7 items with score range from 0 (no disability) to 10 (maximum disability)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient aged 18 and over

  • Patient with cephalalgic syndrome> 3 months,

  • Patient with an indication of first cryoneurolysis

  • Unilateral character of cephalalgic syndrome

  • Failure of oral treatment of stage II

  • Positive response (> 50% efficacy on pain EVA) to infiltration of Arnold's nerve

  • Subject having signed his written participation consent

Exclusion Criteria:
  • Coagulation disorder

  • Infection in progress

  • Patient under anticoagulant

  • Contraindication to performing an MRI:

  1. Any subject with a vascular stent implanted less than 6 weeks before the examination.

  2. Any subject with implanted biomedical material deemed "unsafe" or "unsafe" in the list: http://www.mrisafety.com/TheList_search.asp.

  3. Any acquisition procedure that does not meet the conditions required for "conditional" use in a subject carrying implanted biomedical material deemed "conditional" in the list: http://www.mrisafety.com/TheList_search.asp.

  4. Any subject carrying an intra-ocular or intra-cranial ferromagnetic foreign body close to the nerve structures.

  5. Any subject carrying a biomedical material such as a cardiac, neuronal or sensory stimulator (cochlear implant) or a ventricular bypass valve without medical and paramedical supervision trained to perform MRI in these subjects.

  6. Non-cooperating subject

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHU Grenoble-Alpes Grenoble France 38043

Sponsors and Collaborators

  • University Hospital, Grenoble

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Grenoble
ClinicalTrials.gov Identifier:
NCT03735914
Other Study ID Numbers:
  • 38RC16.242
First Posted:
Nov 8, 2018
Last Update Posted:
Apr 1, 2020
Last Verified:
Mar 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 1, 2020